Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Healthcare Biotechnology
Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and... see more

Recent & Breaking News (TSX:ONC)

Oncolytics Biotech® Inc. Reports Updated Data from Randomized Phase 2 Study of REOLYSIN® in Pancreatic Cancer

Canada NewsWire April 14, 2016

Oncolytics Biotech® Inc. Announces Filing of Management Information Circular and Details of 2016 Annual General Meeting

Canada NewsWire March 24, 2016

Oncolytics Biotech® Inc. Reports Data from Randomized Phase 2 Study of REOLYSIN® in Ovarian Cancer

Canada NewsWire March 21, 2016

Oncolytics Biotech(R) Inc. Announces 2015 Year End Results

Canada NewsWire March 11, 2016

Oncolytics Biotech® Inc. Announces $4.6 Million "At-The-Market" Equity Financing Program

Canada NewsWire February 25, 2016

Media Advisory - Oncolytics Biotech® Inc. Announces Participation in Upcoming Conferences

Canada NewsWire February 8, 2016

Oncolytics Biotech® Inc. Announces First Patients Treated in Phase 1b Study in Advanced Pancreatic Cancer

Canada NewsWire January 19, 2016

Oncolytics Biotech® Inc. Collaborators Present Multiple Myeloma Data at 57th American Society of Hematology Annual Meeting

PR Newswire December 8, 2015

MEDIA ADVISORY - Oncolytics Biotech® Inc. to Present at LD Micro Growth Conference

Canada NewsWire December 2, 2015

Oncolytics Biotech® Inc. Announces Start of Enrollment in Phase 1b Study of Multiple Myeloma Looking at REOLYSIN® in Combination with Bortezomib

Canada NewsWire November 18, 2015

OTC Markets Group Welcomes Oncolytics Biotech® Inc. to OTCQX

PR Newswire November 5, 2015

Oncolytics Biotech® Inc. Announces 2015 Third Quarter Results

Canada NewsWire November 5, 2015

MicroCap Report: Pioneering Technology (V.PTE) pops, Oncolytics (T.ONC) doesn’t make the grade

Stockhouse Editorial October 29, 2015

Oncolytics Biotech® Inc. Announces Receipt of Qualification for Trading on the OTCQX and Nasdaq Notice of Delisting

Canada NewsWire October 29, 2015

Media Advisory - Oncolytics Biotech® Inc. to Participate in the 14th Annual BIO Investor Forum

Canada NewsWire October 20, 2015

Oncolytics Biotech® Inc. Announces Phase 1b Study in Advanced Pancreatic Cancer

Canada NewsWire October 20, 2015

Oncolytics Biotech® Inc. Announces Completion of Enrollment in Randomized Phase II Prostate Cancer Study

Canada NewsWire October 6, 2015

Oncolytics Biotech® Inc. Collaborators Present Data from Clinical Study in Multiple Myeloma

PR Newswire September 25, 2015

Media Advisory - Oncolytics Biotech® Inc. to Participate in the Baird 2015 Healthcare Conference

Canada NewsWire September 9, 2015

Oncolytics Biotech® Inc. Collaborators to Present Survival Data from REO 016 Study in Non-Small Cell Lung Cancer

Canada NewsWire August 27, 2015